TAFFIC TABLET

Taffic tablet is determined as an entire procedure for the medication of human immunodeficiency virus type 1 (HIV-1) infection who has no antiretroviral medication history or to follow the common antiretroviral procedure in those who are virologically-contain on a stable antiretroviral procedure.  Taffic tablet is a permanent dose of mixture medicine for the medication of HIV/AIDS. It consists of 50 mg bictegravir, 200 mg emtricitabine, and 25 mg tenofovir alafenamide.

Mechanism of action:

Bictegravir: BIC prevents the string transfer action of HIV-1 integrase (integrase string transfer prevents; INSTI), an HIV-1 encoded enzyme that is recommended for viral reproduction. Prevention of integrase inhibits the integration of linear HIV-1 DNA into host genomic DNA; prevent the formation of the HIV-1 provirus and reproduction of the virus.

Emtricitabine: FTC is an artificial nucleoside bride of cytidine, is phosphorylated by a cellular stimulant to form emtricitabine 5'-triphosphate. Emtricitabine 5'-triphosphate prevents the action of the HIV-1 reverse transcriptase by contending with the natural substrate deoxycytidine 5'-triphosphate and by actually included in nascent viral DNA which results in chain termination. Emtricitabine 5′-triphosphate is a weak preventer of mammalian DNA polymerases α, β, Ɛ, and mitochondrial DNA polymerase.

Tenofovir Alafenamide: TAF is a phosphoramidite prodrug of tenofovir (2′-deoxyadenosine monophosphate analog). Plasma revelation to TAF admits for transport into cells and then TAF is intracellularly transformed to tenofovir through hydrolysis by cathepsin A. Tenofovir is finally phosphorylated by cellular kinases to the effective metabolite tenofovir diphosphate. Tenofovir diphosphate prevents HIV-1 reproduction through fusion into viral DNA by the HIV reverse transcriptase, which development in DNA chain-termination. Tenofovir diphosphate is a weak preventer of mammalian DNA polymerases that contain mitochondrial DNA polymerase γ and there is no information of toxicity to mitochondria in cell cultivation.

Pharmacokinetics:

1. Absorption

Taffic tablet rapidly absorbed to the body is Tmax is 2.0-4.0hrs, 1.5–2.0 hrs, and 0.5–2.0 hrs. Then Cmax ration is 1.13, 0.86, and 0.92.

2. Distribution

Taffic tablet is the volume of distribution in the blood to plasma ratio is 0.64L, 0.6L, and 1.0L.

3. Metabolism

Emtricitabine is almost 86% unmetabolized. The average half-life of BIC estimated from 15.9 h - 20.9 h. Tenofovir alafenamide is recommended to be determined to the person associate tenofovir by the action of cathepsin A or carboxylesterase 1.

4. Excretion

Taffic tablet is the excretion of the dose is recovered from the urine is 70% & the excretion of the dose is recovered from the feces is 60.3%.

Storage:

Store in a Dry place 30°C (86°F).

• Keep bottle tightly closed.

• Dispense only in the original bottle.

Dosage and Administration:

The suggested dose of Taffic tablet is one tablet taken orally once every day with or without food.

CONTRAINDICATIONS:

 Taffic tablet is contraindicated to be co-conduct with dofetilide expected to the possible for raised dofetilide plasma combination and combine severe and life-aggressive events.

Side-Effects:

The common side effects of Taffic tablet are Depression

Abnormal dreams, Headache, Dizziness, Diarrhea, Feeling sick (nausea), Tiredness (fatigue).

Overdosage:

Hemodialysis medication eliminates almost 30% of the FTC dose over a 3-hour separation time starting within 1.5 hours of FTC dosing (blood flow rate of 400 mL per minute and a dialysate flow rate of 600 mL per minute).

Contact details 
Apple Pharmaceuticals 
Mobile/Viber/Telegram :+919987711567
WeChat : applepharmaceuticals 
Skype : applepharma
qq : 2097734872
Email id :applepharmaceutical@gmail.com
Website : https://myapplepharma.com/